文献速递脑血管病

脑出血后长期血压控制的回顾:挑战与机遇

Review of Long-Term Blood Pressure Control After Intracerebral Hemorrhage: Challenges and Opportunities.
PubMed 文献 · Stroke · 2022-06-03

血压是脑出血最重要的可干预危险因素,急性期收缩压目标<140 mm Hg合理,长期应尽早滴定口服降压药使血压<130/80 mm Hg,所有脑出血患者不论年龄、部位或推测机制均适用。持续降压幅度比降压药选择更重要,单片复方制剂可考虑作为首选。

要点

  • 急性脑出血早期静脉或口服药物使收缩压<140 mm Hg对多数患者合理。
  • 长期口服降压药应尽早滴定至血压<130/80 mm Hg,所有脑出血患者均适用。
  • 持续降压幅度比降压药选择更重要,单片复方制剂可考虑作为管理选择。

核心结论

  • 长期血压控制应尽早滴定口服降压药使血压<130/80 mm Hg,且所有脑出血患者不论年龄、部位或推测机制均适用。
  • 持续降压幅度而非降压药选择是优化风险降低的最重要因素。
  • 单片复方制剂在可获得时应考虑作为管理选择。

研究设计与样本

  • 本文为综述,检索范围未在摘要中报告。

主要发现

  • 血压升高与脑出血风险增加、脑出血后结局更差相关,存活者复发脑出血、缺血性卒中、心肌梗死和认知障碍/痴呆风险更高。
  • 急性脑出血强化降压可能改善恢复机会,早期使用静脉或口服药物在就诊最初几小时内使收缩压<140 mm Hg对多数患者合理。
  • 噻嗪类利尿剂、长效钙通道阻滞剂、ACE抑制剂或血管紧张素受体阻滞剂的不同组合是主要治疗手段。
  • 大多数患者需要多种降压药,医生惰性和依从性差是有效血压控制的主要障碍。

关键数值与推荐

  • 急性期收缩压目标<140 mm Hg,在就诊最初几小时内达到。
  • 长期血压目标<130/80 mm Hg,尽早滴定口服降压药。
  • 单片复方制剂在可获得时应考虑作为管理选择。

临床怎么用

  • 所有医生尤其是管理脑出血患者的医生应在实践中强调血压控制的重要性。
  • 作者认为应增加人群和临床医生意识,并创新解决患者、提供者和社会因素以改善脑出血后血压控制。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Blood pressure (BP) is the most important modifiable risk factor for intracerebral hemorrhage (ICH). Elevated BP is associated with an increased risk of ICH, worse outcome after ICH, and in survivors, higher risks of recurrent ICH, ischemic stroke, myocardial infarction, and cognitive impairment/dementia. As intensive BP control probably improves the chances of recovery from acute ICH, the early use of intravenous or oral medications to achieve a systolic BP goal of <140 mm Hg within the first few hours of presentation is reasonable for being applied in most patients. In the long-term, oral antihypertensive drugs should be titrated as soon as possible to achieve a goal BP <130/80 mm Hg and again in all ICH patients regardless of age, location, or presumed mechanism of ICH. The degree of sustained BP reduction, rather than the choice of BP-lowering agent(s), is the most important factor for optimizing risk reduction, with varying combinations of thiazide-type diuretics, long-acting calcium channel blockers, ACE (angiotensin-converting enzyme) inhibitors or angiotensin receptor blockers, being the mainstay of therapy. As most patients will require multiple BP-lowering agents, and physician inertia and poor adherence are major barriers to effective BP control, single-pill combination therapy should be considered as the choice of management where available. Increased population and clinician awareness, and innovations to solving patient, provider, and social factors, have much to offer for improving BP control after ICH and more broadly across high-risk groups. It is critical that all physicians, especially those managing ICH patients, emphasize the importance of BP control in their practice.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Mullen MT, Anderson CS. Review of Long-Term Blood Pressure Control After Intracerebral Hemorrhage: Challenges and Opportunities. Stroke. 2022. PMID: 35657328. doi:10.1161/STROKEAHA.121.036885

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。